FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032993639> ?p ?o ?g. }

• W2032993639 endingPage "2416" @default.
• W2032993639 startingPage "2408" @default.
• W2032993639 abstract "Background. Numerous treatment strategies have been tried with the aim of improving results for patients with intermediate-grade lymphomas (IGL) over those achieved with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-Bleo), and numerous prognostic models have been developed to identify and separate risk groups. This study reports on a new protocol for Ann Arbor Stages II-IV IGL that consists of CHOP-Bleo alternated with a new regimen of cyclophosphamide, methotrexate, etoposide, and dexamethasone (CMED) and radiation therapy and demonstrates the usefulness of prognostic models for identifying risk groups and comparing treatment programs. Methods. One hundred seventy patients with Ann Arbor Stages II-IV IGL were treated with alternating cycles of CHOP-Bleo and CMED for a total of 12 cycles. Involved field radiation therapy was interspersed with courses of chemotherapy for patients with Stage II and Stage III disease. Results were analyzed and compared with those of the authors' previous study of CHOP-Bleo and radiation therapy using the Ann Arbor staging system, their earlier prognostic model, and the recently published International Index. Results. A complete remission occurred in 78% of the patients. The overall 5-year survival rate was 67%. Survival was better for patients with Ann Arbor Stage II disease (80%) than for those with Stage III or Stage IV (67% and 58%, respectively). High tumor burden, above-normal levels of serum lactic dehydrogenase, serum β2-microglobulin, and Ann Arbor Stage IV disease were adverse factors. The International Index and the authors' earlier prognostic model separated four prognostic groups. CHOP-Bleo/CMED was generally well tolerated. Neutropenic fever was the major complication that occurred in 25 patients during treatment. Six of these patients died of sepsis. Conclusions. This study demonstrated that CHOP-Bleo/CMED is a well-tolerated regimen that produced better results than those reported for a former study that used CHOP-Bleo alone. Further, results for CHOP-Bleo/CMED compared favorably with those of other second and third-generation regimens. The study also validated the usefulness of prognostic models and, in particular, the new International Index for identifying risk groups." @default.
• W2032993639 created "2016-06-24" @default.
• W2032993639 creator A5006742031 @default.
• W2032993639 creator A5021262821 @default.
• W2032993639 creator A5034301588 @default.
• W2032993639 creator A5043765880 @default.
• W2032993639 creator A5047192748 @default.
• W2032993639 creator A5060386553 @default.
• W2032993639 creator A5071173748 @default.
• W2032993639 creator A5078033417 @default.
• W2032993639 creator A5085700191 @default.
• W2032993639 date "1994-05-01" @default.
• W2032993639 modified "2023-09-25" @default.
• W2032993639 title "Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis" @default.
• W2032993639 cites W1492624203 @default.
• W2032993639 cites W1867387438 @default.
• W2032993639 cites W1874309326 @default.
• W2032993639 cites W1898622368 @default.
• W2032993639 cites W1911976151 @default.
• W2032993639 cites W1942762232 @default.
• W2032993639 cites W1948967656 @default.
• W2032993639 cites W2034238565 @default.
• W2032993639 cites W2036711551 @default.
• W2032993639 cites W2057115309 @default.
• W2032993639 cites W2073151455 @default.
• W2032993639 cites W2074609762 @default.
• W2032993639 cites W2094141634 @default.
• W2032993639 cites W2107639967 @default.
• W2032993639 cites W2129001396 @default.
• W2032993639 cites W2143594378 @default.
• W2032993639 cites W2200858253 @default.
• W2032993639 cites W2225850991 @default.
• W2032993639 cites W2229202339 @default.
• W2032993639 cites W2243140240 @default.
• W2032993639 cites W2255096282 @default.
• W2032993639 cites W2273109191 @default.
• W2032993639 cites W2317128933 @default.
• W2032993639 cites W2318772898 @default.
• W2032993639 cites W2441631741 @default.
• W2032993639 cites W4205736005 @default.
• W2032993639 cites W4252168887 @default.
• W2032993639 cites W4293241248 @default.
• W2032993639 doi "https://doi.org/10.1002/1097-0142(19940501)73:9<2408::aid-cncr2820730926>3.0.co;2-m" @default.
• W2032993639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7513251" @default.
• W2032993639 hasPublicationYear "1994" @default.
• W2032993639 type Work @default.
• W2032993639 sameAs 2032993639 @default.
• W2032993639 citedByCount "17" @default.
• W2032993639 crossrefType "journal-article" @default.
• W2032993639 hasAuthorship W2032993639A5006742031 @default.
• W2032993639 hasAuthorship W2032993639A5021262821 @default.
• W2032993639 hasAuthorship W2032993639A5034301588 @default.
• W2032993639 hasAuthorship W2032993639A5043765880 @default.
• W2032993639 hasAuthorship W2032993639A5047192748 @default.
• W2032993639 hasAuthorship W2032993639A5060386553 @default.
• W2032993639 hasAuthorship W2032993639A5071173748 @default.
• W2032993639 hasAuthorship W2032993639A5078033417 @default.
• W2032993639 hasAuthorship W2032993639A5085700191 @default.
• W2032993639 hasBestOaLocation W20329936391 @default.
• W2032993639 hasConcept C126322002 @default.
• W2032993639 hasConcept C141071460 @default.
• W2032993639 hasConcept C143998085 @default.
• W2032993639 hasConcept C2776232574 @default.
• W2032993639 hasConcept C2776694085 @default.
• W2032993639 hasConcept C2776755627 @default.
• W2032993639 hasConcept C2778119113 @default.
• W2032993639 hasConcept C2778476033 @default.
• W2032993639 hasConcept C2778720950 @default.
• W2032993639 hasConcept C2779338263 @default.
• W2032993639 hasConcept C2779429289 @default.
• W2032993639 hasConcept C2779725641 @default.
• W2032993639 hasConcept C2780653079 @default.
• W2032993639 hasConcept C2781214270 @default.
• W2032993639 hasConcept C2781413609 @default.
• W2032993639 hasConcept C71924100 @default.
• W2032993639 hasConcept C90924648 @default.
• W2032993639 hasConceptScore W2032993639C126322002 @default.
• W2032993639 hasConceptScore W2032993639C141071460 @default.
• W2032993639 hasConceptScore W2032993639C143998085 @default.
• W2032993639 hasConceptScore W2032993639C2776232574 @default.
• W2032993639 hasConceptScore W2032993639C2776694085 @default.
• W2032993639 hasConceptScore W2032993639C2776755627 @default.
• W2032993639 hasConceptScore W2032993639C2778119113 @default.
• W2032993639 hasConceptScore W2032993639C2778476033 @default.
• W2032993639 hasConceptScore W2032993639C2778720950 @default.
• W2032993639 hasConceptScore W2032993639C2779338263 @default.
• W2032993639 hasConceptScore W2032993639C2779429289 @default.
• W2032993639 hasConceptScore W2032993639C2779725641 @default.
• W2032993639 hasConceptScore W2032993639C2780653079 @default.
• W2032993639 hasConceptScore W2032993639C2781214270 @default.
• W2032993639 hasConceptScore W2032993639C2781413609 @default.
• W2032993639 hasConceptScore W2032993639C71924100 @default.
• W2032993639 hasConceptScore W2032993639C90924648 @default.
• W2032993639 hasIssue "9" @default.
• W2032993639 hasLocation W20329936391 @default.
• W2032993639 hasLocation W20329936392 @default.
• W2032993639 hasOpenAccess W2032993639 @default.
• W2032993639 hasPrimaryLocation W20329936391 @default.

• next